A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples